Overview

Efficacy and Safety Study of Acetylcysteine/Doxofylline 1200/400 mg Effervescent Tablet in the Treatment of Moderate-Severe COPD.

Status:
Completed

Trial end date:
2019-12-21

Target enrollment:

Participant gender:

Summary

The objective is to assess efficacy and safety of Acetylcysteine/Doxofylline 1200/400 mg Effervescent Tablet once daily treatment besides standard/usual treatment, as compared with placebo once daily in patients with stable moderate to severe COPD.

Phase:

Phase 4

Details

Lead Sponsor:

Neutec Ar-Ge San ve Tic A.Ş

Treatments:

Acetylcysteine
Doxofylline
N-monoacetylcystine